<DOC>
	<DOCNO>NCT00843232</DOCNO>
	<brief_summary>Type 2 diabetes ( T2DM ) characterize hyperglycemia , insulin resistance , absolute relative insulin deficiency , hyperglucagonemia , increase hepatic glucose production , frequently accelerate gastric empty obesity . The known effect incretin hormone glucagon-like peptide-1 ( GLP-1 ) metabolism stimulation insulin secretion , inhibition glucagon secretion hepatic glucose production , reduction gastric empty modulation appetite . T2DM disturbances system , provide rationale therapeutic use GLP-1 T2DM . Furthermore , GLP-1 seem exert trophic effect beta-cell . Dipeptidyl Peptidase IV ( DPP-IV ) inhibitor represent new class oral anti-hyperglycemic agent treatment T2DM . The therapeutic utility antihyperglycemic agent rest ability increase active ( intact ) level incretin peptide , include GLP-1 GIP . Twenty four T2DM volunteer evaluate meal tolerance test ( MTT ) incretin hormone measurement , hyperglycemic clamp follow arginine test assess beta-cell function acute insulin response . Others parameter body composition basic biochemistry also evaluate Laboratory Investigation Metabolism Diabetes - LIMED / State university Campinas , Brazil . T2DM elderly behaving differently . Elderly patient increase liver production glucose ; obese , normal insulin secretion , however , display extreme resistance action . In non obese individual , concentration glucose necessary insulin secretion increase action standard . These finding suggest therefore approach differentiate treatment individual .</brief_summary>
	<brief_title>Characterization Incretinpathy Type 2 Diabetes Initiated After Sixty Years Old</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<criteria>Stable weight ( &lt; 5 % variation ) within last three month Age : 35 50 year old middleage group , 65 80 old elderly group Body mass index ( BMI ) : 20 29.9kg/m2 T2DM diagnosis 35 year less 5 year ( Middleage group ) T2DM diagnosis 65 year less 5 year ( Elderly group ) Use oral antidiabetic drug ( must stable dose within last 3 month ) Not participate study intervention drug last six month . Use estrogen , progestogen , active antipsychotic systemic corticosteroid Use DPPIV inhibitor incretin mimetics ( current within 1 month ) Continuous use insulin glitazone Hepatic cirrhosis , renal failure clinical condition impair insulin sensitivity Smoking Obesity Uncontrolled systemic disable disease T2DM treat non pharmacological method Patients submit bariatric surgery Latent autoimmune diabetes adult ( positive antiGAD antibody )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>diabetes mellitus , type 2</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Aging</keyword>
	<keyword>Incretins</keyword>
	<keyword>DPP-IV protein , human</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Gastric Inhibitory Polypeptide</keyword>
	<keyword>insulin</keyword>
	<keyword>glucagon</keyword>
	<keyword>ghrelin</keyword>
</DOC>